Global Retirement Partners LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 23.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 832 shares of the company’s stock after selling 259 shares during the period. Global Retirement Partners LLC’s holdings in IDEXX Laboratories were worth $420,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. Riverview Trust Co purchased a new position in IDEXX Laboratories in the 1st quarter worth approximately $26,000. Crewe Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter valued at $26,000. Ridgewood Investments LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $27,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $28,000. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Stock Down 1.0 %
Shares of NASDAQ IDXX opened at $453.38 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The firm has a market capitalization of $37.44 billion, a PE ratio of 43.89, a price-to-earnings-growth ratio of 4.14 and a beta of 1.33. The firm has a fifty day simple moving average of $486.97 and a two-hundred day simple moving average of $490.87.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. JPMorgan Chase & Co. lowered their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, Piper Sandler lowered their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $574.13.
Get Our Latest Stock Report on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Recommended Stories
- Five stocks we like better than IDEXX Laboratories
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Industrial Products Stocks Investing
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.